Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab-based alternative regimens for diffuse large B-cell lymphoma unsuitable for standard treatment
ISRCTN11542980Phase 2Completed
- Sponsor
- Clatterbridge Cancer Centre
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Clatterbridge Cancer Centre. Primary endpoint: Progression-free survival. Started May 2022; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN11542980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11542980.